UA97229C2 - Isolated monoclonal antibody that specifically binds to toll like receptor 3 (tlr3) - Google Patents
Isolated monoclonal antibody that specifically binds to toll like receptor 3 (tlr3)Info
- Publication number
- UA97229C2 UA97229C2 UAA200706796A UAA200706796A UA97229C2 UA 97229 C2 UA97229 C2 UA 97229C2 UA A200706796 A UAA200706796 A UA A200706796A UA A200706796 A UAA200706796 A UA A200706796A UA 97229 C2 UA97229 C2 UA 97229C2
- Authority
- UA
- Ukraine
- Prior art keywords
- antibody
- tlr3
- toll
- receptor
- specifically binds
- Prior art date
Links
Landscapes
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to an isolated monoclonal antibody that specifically binds to Toll Like Receptor 3 (TLR3) and inhibits cellular production of RANTES cytokine (Regulated on Activation, Normal T-cell Expressed and Secreted; chemokine isolated by T-cells on activation), a polynucleotide encoding the antibody, a vector, a host-cell, a hybridoma cell line and method of making the antibody. The invention further relates to a poharmaceutical composition comprising the antibody, a method of inhibiting cellular production of RANTES, a method of treating or preventing an inflammatory condition, a method of increasing the proliferation rate of a cell etc.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63181504P | 2004-11-30 | 2004-11-30 | |
PCT/US2005/043373 WO2006060513A2 (en) | 2004-11-30 | 2005-11-30 | Toll like receptor 3 antagonists, methods and uses |
Publications (1)
Publication Number | Publication Date |
---|---|
UA97229C2 true UA97229C2 (en) | 2012-01-25 |
Family
ID=40595561
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA200706796A UA97229C2 (en) | 2004-11-30 | 2005-11-30 | Isolated monoclonal antibody that specifically binds to toll like receptor 3 (tlr3) |
Country Status (4)
Country | Link |
---|---|
CN (1) | CN101415438B (en) |
SG (1) | SG158098A1 (en) |
UA (1) | UA97229C2 (en) |
ZA (1) | ZA200705206B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT2350304T (en) * | 2008-10-31 | 2017-02-10 | Janssen Biotech, Inc. | Toll-like receptor 3 antagonists |
IE20090514A1 (en) * | 2009-07-06 | 2011-02-16 | Opsona Therapeutics Ltd | Humanised antibodies and uses therof |
BR112014005786A2 (en) * | 2011-09-12 | 2017-03-28 | Janssen Biotech Inc | toll-3 receptor antagonists for the treatment of metabolic and cardiovascular diseases |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1721443A (en) * | 2000-05-25 | 2006-01-18 | 先灵公司 | Human receptor proteins, related reagents and methods |
-
2005
- 2005-11-30 SG SG200907955-9A patent/SG158098A1/en unknown
- 2005-11-30 CN CN200580047396.4A patent/CN101415438B/en active Active
- 2005-11-30 UA UAA200706796A patent/UA97229C2/en unknown
-
2007
- 2007-06-29 ZA ZA200705206A patent/ZA200705206B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN101415438B (en) | 2013-03-27 |
SG158098A1 (en) | 2010-01-29 |
ZA200705206B (en) | 2009-01-28 |
CN101415438A (en) | 2009-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA97946C2 (en) | Monoclonal antibody which specifically binds to an extracellular domain of human ilt7 | |
HUS2100051I1 (en) | Compositions and methods of treating cell proliferation disorders | |
NZ712762A (en) | Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r | |
IL189726A0 (en) | Il-17a and il-17f antagonists and methods of using the same | |
WO2004045525A3 (en) | Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation. | |
MXPA06014465A (en) | Soluble zcytor14, anti-zcytor14 antibodies and binding partners and methods of using in inflammation. | |
MX2013002906A (en) | High-strength steel sheet with excellent ductility and stretch flangeability, high-strength galvanized steel sheet, and method for producing both. | |
MX360332B (en) | High-strength galvanized steel sheet having superior bendability and method for producing same. | |
MX2007010833A (en) | Use of opioid antagonists to attenuate endothelial cell proliferation and migration. | |
WO2005116236A3 (en) | Methods for treating cancer using anti-wnt2 monoclonal antibodies and sirna | |
SG146624A1 (en) | Cytokine inhibitors | |
ZA200806610B (en) | Anti-IL-6 antibodies preventing the binding of IL-6 complexed with IL-6ralpha to GP130 | |
MX341370B (en) | Humanized anti-beta7 antagonists and uses therefor. | |
SG170082A1 (en) | Methods for regulating inflammatory mediators and peptides useful therein | |
UA94484C2 (en) | Antibodies to lymphotoxin-alpha | |
WO2008133684A8 (en) | Antibodies that bind both il-17a and il-17f and methods of using the same | |
UA97229C2 (en) | Isolated monoclonal antibody that specifically binds to toll like receptor 3 (tlr3) | |
MX2020010281A (en) | High-strength galvanized steel sheet, high-strength member, and manufacturing methods therefor. | |
MX2009000975A (en) | Methods for attenuating release of inflammatory mediators and peptides useful therein. | |
TW200740842A (en) | Monoclonal antibodies, hybridoma cell lines, methods and kits for detecting phytase | |
MX2022012823A (en) | Engineered il-12 and il-23 polypeptides and uses thereof. | |
WO2005040121A3 (en) | Amides that inhibit vanilloid receptor subtype 1 (vr1) receptor | |
EP2536430A4 (en) | Compositions and methods for targeting type 1 interferon producing cells | |
MX2007004597A (en) | Soluble zcytor21, anti-zcytor21 antibodies and binding partners and methods of using in inflammation. | |
MX2007000364A (en) | Methods for treating cancer using agents that inhibit wnt16 signaling. |